ARTL beat EPS expectations by 25.94%
Nov 22, 2024, 11:32 PM
0.17%
What does ARTL do
Artelo Biosciences, a clinical-stage biopharmaceutical company based in Solana Beach, California, focuses on developing therapeutics targeting lipid-signaling pathways and the endocannabinoid system. Its key programs include ART27.13 for anorexia and ART26.12 for cancer, pain, and anxiety.
Artelo Biosciences (ARTL) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Artelo Biosciences's actual EPS was -$0.35, beating the estimate of -$0.47 per share, resulting in a 25.94% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.